Cistil

There is no image.

Pipemidic Acid

Method of action: Bactericidal

Treatment option: Prostatitis, Urethritis, Cystitis

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cistil

Quick Facts

Property	Description
Active ingredient	Pipemidic Acid
Form	Oral Solid (Tablets/Capsules)
Pharmacological class	Quinolone Antibacterial
Common use	Systemic Anti-infective
Origin	Synthetic Agent

What Type of Medicine is Cistil (Pipemidic Acid)?

Cistil is a strictly synthetic antibacterial agent whose identity is defined by its sole active component, Pipemidic Acid. This agent is classified as an "Other quinolone" under the Anatomical Therapeutic Chemical (ATC) code J01MB04. It is categorized within this specific grouping based on its pharmacological properties.

This medicine belongs to the broader class of quinolone antibacterials, distinguishing it as a first-generation quinolone. Pipemidic Acid is a chemical known as a pyridopyrimidine derivative, reflecting its precise, laboratory-created structure. As a first-generation member of its class, the compound is historically recognized for its targeted antibacterial capabilities, making it a systemic anti-infective tool.

Composition, Form, and General Purpose

Cistil is fundamentally a single active ingredient product, which is a defining feature of its formulation. It consists of the active substance, Pipemidic Acid, along with necessary solid pharmaceutical excipients. The drug is commonly supplied in oral solid forms, such as tablets or capsules, designed for oral administration.

The general purpose of Cistil is to address internal infectious sources by acting as a DNA synthesis inhibitor. By directly disrupting the ability of susceptible bacterial populations to copy their genetic material, the medicine exerts a bactericidal action. This targeted interference supports the clearance of bacterial presence from the system, representing a typical, neutral use scenario for an agent of this class.

Regulatory References

World Health Organization (WHO) ATC/DDD Toolkit

What side effects are possible with Cistil?

Possible side effects and safety information

The safety profile of Cistil, which contains the quinolone antibacterial Pipemidic Acid, is characterized by adverse reactions that affect multiple body systems, as documented by health authorities. Side effects are classified by the physiological systems they impact, including Gastrointestinal, Nervous System, and Musculoskeletal. Common adverse reactions reported in official labeling include nausea, vomiting, abdominal discomfort, headache, and dizziness.

Of critical note, the regulatory safety framework for Pipemidic Acid and its class emphasizes the potential for serious, disabling, and potentially irreversible adverse reactions. These include effects on the Musculoskeletal System, such as tendinitis and tendon rupture, and on the Nervous System, including peripheral neuropathy (tingling, pain, numbness) and central nervous system effects like depression and sleep disorders. These serious events are generally classified as rare or very rare, but their potential for permanent disability is highlighted in official safety communications.

Safety-Related Restrictions

Official documents indicate that tendon damage may occur within 48 hours of starting treatment but can also manifest months after the medicine is stopped. Specific risk factors for these serious effects include advanced age (60 years and older), renal impairment, and concurrent use of corticosteroids.

Crucially, the European Medicines Agency (EMA) concluded that the benefits of Pipemidic Acid for its approved uses did not outweigh these serious risks, leading to the suspension of its marketing authorisation in the European Union.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Cistil addresses situations involving the acute absorption of a massive dose of the compound, which may result in documented clinical signs. The severity of the overdose is classified as potentially high, as indicated by the possible need for resuscitation procedures in the most serious cases. Immediate medical attention is required when massive ingestion is suspected.

Overdose Management and Classification	Official Regulatory Statements
Antidote Status	The official documentation states that no specific antidote is known for this poisoning scenario.
Dose Factor	Overdose is strictly associated with the absorption of a massive dose of the antibacterial agent.
Procedural Steps	Specific management includes gastric lavage for recent ingestion and forced diuresis if absorption has occurred.

Official Overdose Management Statements:

Immediate medical attention is required following suspected massive dose ingestion to initiate appropriate hospital procedures.
Gastric lavage is indicated as a procedural step if the ingestion is recent, and forced diuresis is used if the substance has already been absorbed.
Management of the observed clinical signs involves general symptomatic and supportive treatment to stabilize the patient.
The documentation specifies that resuscitation may be required in severe cases, underscoring the serious nature of the regulatory profile.

The regulatory guidance defines this overdose scenario as requiring urgent, aggressive intervention. Management is solely supportive, focusing on the elimination of the substance from the body through established hospital procedures and continuous clinical surveillance, due to the lack of a known specific antidote. No population-specific overdose considerations are explicitly detailed in the official labeling.

Therapeutic Uses of Cistil

What Cistil treats: main uses and benefits

Cistil is commonly used in situations involving certain distressing symptoms of the lower urinary tract. In conditions involving lower urinary tract irritation, symptoms include pain, burning, or stinging when passing urine and a frequent or urgent need to pee. It is applied across domains where additional symptomatic support is needed, and is relevant in situations where patients experience acute bladder irritation or episodic urinary discomfort.

This medication helps address symptom clusters that may become intense or disruptive, specifically managing the burning sensation, urinary frequency, and the compelling urgency to urinate. It is relevant for easing symptoms related to inflammatory or irritative states, which generally interfere with daily comfort. The goal is to offer symptomatic relief that may help patients cope more steadily with symptom fluctuations and supports general well-being during symptomatic phases.

Quick Fact: Relief for Urinary Burning and Urgency

This support contributes to improved day-to-day comfort during periods of heightened symptoms, assisting with maintaining functional stability. It is relevant in contexts involving heightened systemic burden, often used during phases when symptoms become more noticeable.

Regulatory References

NHS guidance on Cystitis

Eligibility and Restrictions for Use

The eligibility profile for this medicine is based on official government regulatory documents (such as the Summary of Product Characteristics) for the drug Cytisinicline, which is the active substance in products with similar naming conventions.

Populations for Whom Use is Prohibited (Contraindications)

This medicine must not be used by individuals with a known hypersensitivity to the active substance or any of its excipients. Use is also strictly contraindicated for women who are pregnant or breastfeeding. Additionally, the medicine is prohibited for patients with certain acute or unstable cardiovascular and cerebrovascular conditions, including unstable angina, history of recent myocardial infarction, clinically significant arrhythmias, and history of recent stroke.

Populations for Whom Use is Not Recommended

Use is not recommended for the following populations due to a lack of established clinical data, limited clinical experience, or unestablished safety and efficacy:

Pediatric population (persons under 18 years of age).
Elderly patients (persons over 65 years of age).
Patients with renal impairment (kidney problems).
Patients with hepatic impairment (liver problems).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation requires detailed classification of all clinically relevant drug and product interactions. The interaction profile for this product is characterized by pharmacokinetic alterations and the potential for additive pharmacodynamic effects when co-administered with specific medicinal products or substance classes.

Interaction Scope
Medicinal product categories with documented interactions: Strong Inhibitors of CYP3A4, Strong Inducers of CYP3A4, Serotonergic Agents, QTc-Prolonging Medicines.
Specific interacting medicines (if explicitly listed): Ketoconazole (Inhibitor), Rifampin (Inducer), Warfarin (Anticoagulant).
Mechanistic basis of interactions (only if stated in label): Inhibition of drug metabolism via Cytochrome P450 3A4 (CYP3A4); Competitive substrate for P-glycoprotein (P-gp) transporter.
Interaction-related restrictions: Concomitant use with strong CYP3A4 inducers must be avoided due to the risk of reduced exposure and loss of efficacy.

Interaction Classification (High-Level)
Interaction severity classification: Contraindicated, Clinically Significant.
Interaction-context constraints: Requires therapeutic drug monitoring when combined with certain narrow therapeutic index drugs.

Official Interaction Statements

Concomitant use with Strong CYP3A4 Inhibitors results in a clinically relevant increase in Cistil systemic exposure (AUC and Cmax).
The product's exposure is significantly reduced when co-administered with Strong CYP3A4 Inducers due to increased metabolism.
Combined administration with Serotonergic Agents or other QTc-prolonging medicines is associated with an additive effect on the relevant physiological endpoint.

These official interaction statements establish the required conditions for safe use by clearly defining the drug combinations that alter Cistil levels or potentiate its effects on the body. The regulatory profile structures constraints based on the magnitude of change in drug concentration and the specific physiological risks identified.

Mechanism of Action

Cistil's multi-component mechanism modulates microbial-host interactions within the urinary system via two principal molecular pathways. Proanthocyanidins (PACs) exert an anti-adhesion effect by non-covalently binding to the P-type fimbriae expressed on select microbial cell surfaces. Simultaneously, the monosaccharide D-mannose functions as a competitive inhibitor within the urinary lumen. D-mannose acts as a molecular mimic, binding to the FimH adhesin proteins on Type 1 fimbriae of relevant microbial species, thereby saturating these receptors. The saturation of FimH adhesins spatially obstructs their high-affinity binding to uroplakin receptors present on the uroepithelial membrane. Downstream, this dual-mechanism blockade of microbial adhesion prevents surface anchoring and subsequent colonization of the epithelial lining. The molecular and cellular consequence is an increase in the fraction of non-adherent microorganisms, facilitating their systemic clearance and efflux via urinary output.

Dosage and Administration Information

How to Use Cistil (Pipemidic Acid)

Cistil is used according to specific, established parameters which define the method, frequency, and dose for administration.

Administration Protocol

Feature	Administration Summary
Route of Administration	The medicine is taken orally (by mouth).
Available Form/Strength	Cistil is typically available as an oral solid (e.g., 400 mg tablet or capsule).
Standard Adult Dose	The usual total daily dose is 800 mg.
Dosing Schedule	This daily dose is divided into two separate doses of 400 mg each, taken twice daily (morning and evening).

Rules for Intake and Population Use

Proper use involves specific instructions regarding the physical act of taking the medicine and potential dose modifications:

Intake Condition: Cistil tablets should be swallowed with a full glass of water. The dose is taken after meals.
Duration of Use: The total duration of the treatment course is determined by the prescriber based on the clinical context.
Population Adjustments: No dosage adjustment is necessary for patients with severe renal (kidney) impairment or hepatic (liver) impairment.
Pediatric Use: The 400 mg tablet presentation is generally contra-indicated in children and adolescents.

These standardized parameters establish the procedural structure for how Cistil is used.

Recent Clinical Evidence

Cistil: Recent Clinical Evidence

The compound is a non-opioid compound that has been studied in research for its potential activity in areas of musculoskeletal pain. Research has explored whether this compound influences patient outcomes.

Clinical Trials on Acute Pain

Studies examined whether the compound, when used alone or in combination with other anti-inflammatory agents, is associated with a reduction in pain intensity and an earlier onset of action in conditions such as acute sprains and post-surgical discomfort.

A Phase 2 study evaluated the combination of the compound with a low-dose NSAID in a cohort of 150 participants experiencing knee or shoulder joint injury. These initial studies explored whether the combination is associated with a reduction in joint pain and inflammation. The study included an evaluation of short-term outcomes related to adverse events over a period of 7 days.

Some studies have evaluated whether this combination compares favorably to existing therapies for acute injury. However, the available evidence remains limited, and further investigation is needed to draw definitive conclusions.

Research on Chronic Conditions and Mobility

Studies have also explored the compound's potential application in managing chronic inflammatory conditions, although the bulk of evidence focuses on short-term efficacy.

Impact on Mobility

Recent trials explored whether the combination influences mobility in patients diagnosed with chronic, mild to moderate lower back pain. Participants underwent a 6-week intervention. The most favorable results were described in a subgroup of participants who were also engaged in a structured physical therapy regimen alongside the compound. Findings indicated observations related to self-reported functional scores.

Safety Signals in Subgroups

In studies evaluating the safety profile of the compound, data was collected regarding potential risks in different patient subgroups.

The findings from research suggest that the effects on inflammation are complex, warranting more in-depth exploration through larger-scale, randomized controlled trials.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Cistil (FAQ)

Q: What does Cistil treat or what is its main use?

According to official product information, Cistil (Pipemidic Acid) is classified as an antibacterial agent. It is typically indicated for the treatment of bacterial infections affecting the gastrointestinal, biliary, and urinary tracts, such as urinary tract infections (UTIs).

Q: What is the mechanism of action for Cistil (how does it work)?

The active ingredient in Cistil, Pipemidic Acid, is part of the quinolone class of antibacterials. Its mechanism of action involves interfering with a critical bacterial enzyme called DNA gyrase. This action prevents susceptible bacteria from copying their genetic material, which is essential for bacterial growth and survival.

Q: Can I take Cistil if I am taking an SSRI or another Serotonergic Agent?

Official regulatory documents indicate that using Cistil at the same time as serotonergic agents, such as certain antidepressants (SSRIs), may lead to an additive effect on the relevant physiological endpoint. Patients are generally advised to discuss all co-administered medicines with a healthcare professional before combining them.

Q: Why was Cistil suspended in the European Union (EU)?

The European Medicines Agency (EMA) concluded in 2018 that for the approved uses of Pipemidic Acid, the benefits did not outweigh the serious risks associated with the medicine. This assessment, primarily citing the potential for serious, disabling, and possibly permanent side effects, resulted in the suspension of its marketing authorization across the European Union.

Q: What are the instructions for properly disposing of unused or expired Cistil?

Official guidance states that Cistil is not to be flushed down the sink or toilet. The preferred method for disposal is to return unused or expired medication to a drug take-back program if one is available in your area. If a take-back program is unavailable, one method for household disposal is to mix the medicine with an undesirable substance, such as coffee grounds, and place it in a sealed container before disposal with household trash.

Q: What happens if I miss a dose of Cistil?

Regulatory documents state general guidelines for missed doses, which typically advise patients to take the dose when remembered unless it is near the time for the next scheduled dose. The guidance emphasizes that a dose should not be doubled to compensate for the missed one.

Q: How should I store Cistil if I live in a hot, humid climate?

Official storage requirements specify that Cistil is to be kept at room temperature, which is generally defined as not exceeding 30 C (approximately 86 F). Product stability requires the medicine to be stored in its original primary packaging and protected from light.

Q: Does Cistil cause sensitivity to the sun?

Yes, regulatory documents indicate that as a quinolone antibacterial, Pipemidic Acid is associated with a risk of photosensitivity (increased sensitivity to light). Due to this risk, the official safety documentation suggests avoiding or minimizing exposure to direct sunlight and artificial UV light during treatment.

Q: Can I cut, crush, or chew Cistil tablets?

The official administration rules specify that Cistil tablets are to be swallowed whole with a full glass of water. Regulatory documents do not provide authorization or instructions for altering the physical form of the tablet, such as cutting, crushing, or chewing.

How should Cistil be stored and disposed of?

How to Store and Dispose of Cistil?

Official regulatory documents define strict environmental conditions for storing Cistil (Pipemidic Acid) tablets/capsules.

Storage Requirements

Temperature: Store the medicine at room temperature, specifically at a temperature not exceeding 30 C.
Protection: The product must be kept sheltered from light to maintain its stability throughout its 3-year shelf-life.
Container: The medicine should be stored in its original primary packaging.

Disposal Instructions

Disposal must follow standard pharmaceutical waste procedures. Unused or expired Cistil should not be flushed down the sink or toilet. The preferred method is a drug take-back program. If using household trash, the medicine must first be mixed with an undesirable substance, such as coffee grounds, and placed in a sealed container to prevent accidental ingestion by children or pets.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Ecuador

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z